Zevra Therapeutics Inc
ZVRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$683.37M
Close$
$-10.42
193.2% downside
Current Fair Value
193.2% downsideOvervalued by 193.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $683.37 Million |
|---|---|
| Enterprise Value | $558.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 0.85 |
| Outstanding Shares | 59,155,970 |
Return
| Return on Equity | 26.37% |
|---|---|
| Return on Assets | 18.96% |
| Return on Invested Capital | 30.86% |
Valuation & Multiples
| P/E Ratio | 12.04 |
|---|---|
| PEG | -13.64 |
| Price to Sales | 5.59 |
| Price to Book Ratio | 3.73 |
| Enterprise Value to Revenue | 4.11 |
| Enterprise Value to EBIT | 7.13 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$33.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$37.08 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.44% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.84%▼ 52.90% |
|---|---|
| Total Invested | $149.36M▼ 61.16% |
| Investors Holding | 57▼ 101.00% |
ESG Score
No data
About Zevra Therapeutics Inc
24 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...